Trial Profile
A Double-Blind, Randomized, Multicenter, Placebo-Controlled, Parallel, Fixed-Dose Study to Evaluate the Efficacy and Safety of MT-5199 for the Treatment in Patients With Tardive Dyskinesia (J-KINECT)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Valbenazine (Primary)
- Indications Drug-induced dyskinesia
- Focus Registrational; Therapeutic Use
- Acronyms J-KINECT
- Sponsors Mitsubishi Tanabe Pharma America; Mitsubishi Tanabe Pharma Corporation
- 02 Jun 2023 Results of 3 studies (KINECT 3, KINECT 4 & J-KINECT) presented in a Neurocrine Biosciences Media Release.
- 02 Jun 2023 According to a Neurocrine Biosciences Media Release, data were presented at 2023 Psych Congress Elevate in Las Vegas.
- 13 Aug 2022 Results published in the Psychiatry and Clinical Neurosciences